The drug company's market value in the two weeks since it went public is over 100 billion! It's called "Maotai in medicine"

"Pharmaceutical Network Corporate News" Gan Li Pharmaceuticals since June 29 landed on A-shares, listed for two weeks, after 12 trading days all up and down, Gan Li Pharmaceuticals ushered in a new peak in market valueas of the close of trading on July 14, ganli Pharmaceuticals' total market value has reached 104.4 billion yuan, at 260.16 yuan per share, up 310.87 percent from the issue price of 63.32 yuan per sharefor the stock price continued to rise and fall, Gan Li Pharmaceuticals also said that it has received three times the stock exchange inquiry letter, Gan Li Pharmaceuticals in the reply to the letter, said that the company is operating normally, the market environment, industry policy did not have a major adjustment, production costs and sales, such as no major fluctuations, normal internal production and operation order, but also denied the existence of major matters should be disclosed but not disclosed major news, as well as media reports, market rumors, hot market concepts, according to public information, Gan Li Pharmaceutical was founded in 1998, headquartered in Beijing, is a scientific research, development, production and sales of high-tech biopharmaceutical enterprisesits main products, including recombinant insulin glargine injection (commodity name: Changxiu), recombinant insulin injection (commodity name: quick show, refined protein zinc recombinant insulin-recombinant insulin mixture injection (25R)'s main revenue, from the sales revenue of insulin preparations and insulin dry powder, insulin preparation sales revenue as a percentage of the main business revenue in 2017-2019, 96.45%, 98.35% and 95.10%, respectivelyat present, as a new share of insulin, Gan Li Pharmaceutical's total market value has far exceeded Tonghua Dongbao, nearly three times itscan be seen from the above, Ganli pharmaceutical revenue is mainly from insulin products, and its much-needed capital attention and favor is also because of insulin productsAccording to data released by the, the number of people with diabetes in China will be about 116 million in 2019, and China has become the world's largest country with diabetes, while the number of diabetics continues to grow rapidly, with IDF predicting that the number of people with diabetes in China will reach 151 million in 2040insulin is one of the effective drugs to treat diabetes, in China's diabetes treatment drug market, although the market share of insulin preparation products decreased slightly from 37.01 percent in 2012 to 35.86 percent in 2016, but still ranked first among all kinds of drugs, according to hospital terminal data for 2018, the third generation of insulin market share is 72%, and there is room for upwardat present, the development of insulin drug has developed from one generation to three generations, Gan Li Pharmaceutical is the representative enterprise of three generations of recombinant insulin, but also a few domestic enterprises that have mastered the core technology of 1-3 generation insulinits core products are called recombinant insulin glargine, and in 2019 recombinant insulin glargine and insulin are included in the 2019 National List of Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs, ganley pharmaceutical seis, this effectively releases the demand for insulin drugs for diabetics in fact, in recent years, in the Chinese market, the sales of long-acting insulin, represented by insulin glargine, is growing rapidly, outpacing other insulin varieties expects the market share of long-acting recombinant insulin analogues to increase in the domestic market in the future in this context, Ganli Pharmaceuticals sales will continue to grow but it is worth noting that more than 90% of revenue has been dependent on insulin preparation sales revenue, so that GanLi Pharmaceuticals is gradually falling into a dominant product structure single situation other high sales costs, but also the performance of Ganli Pharmaceuticals has been overshadowed by the growth in general, in front of Gan Li Pharmaceuticals is not a way, it can follow the incidence of diabetes in the country all the way to the nuggets , on the contrary, ready-to-go national band purchases could also be fatal whether the future of Ganli Pharmaceuticals can continue to be brilliant, or need time and the market to prove .